AEZS - エテルナ・ゼンタリス (AEterna Zentaris Inc.) エテルナ・ゼンタリス

 AEZSのチャート


 AEZSの企業情報

symbol AEZS
会社名 AEterna Zentaris Inc (エテルナ・ゼンタリス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エテルナ・ゼンタリス(AEterna Zentaris Inc.)は腫瘍と内分泌療法を専門にする医薬品開発企業。同社の製品パイプラインは創薬から市販製品までの開発のすべての段階における化合物を含む。腫瘍における優先順位は多発性骨髄腫に対するペリホシンを投与したフェーズ3プログラムと転移性大腸癌を含む多発性癌に対するフェーズ2プログラム、並びに進行性子宮内膜癌と進行性卵巣癌に対するAEZS-108を投与したフェーズ2プログラム、また他の癌適応症における潜在的な発展を含む。内分泌では同社のプログラムは成人成長ホルモン分泌不全症(AGHD)の診断のための成長ホルモン(GH) 刺激試験とするAEZS-130(SolorelTM)を投与したフェーズ3相試験の再活性化である。   エテルナ・ゼンタリスはカナダのバイオ医薬品メ―カ―。腫瘍及び内分泌疾患の治療法の開発、商業化に従事。パイプラインは、薬品の発見から開発、製品の販売までが含まれる。製品候補には、小児充実性腫瘍、子宮内膜がん、卵巣がん、前立腺がん、がん悪液質などの新治療薬がある。本社はカナダケベック州。   Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company's lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen™through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. According to a commercialization and supply agreement, MegaPharm Ltd. will seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will be marketed in Europe and the United Kingdom through a recently established license agreement with Consilient Health Ltd and Aeterna Zentaris will receive royalties on sales and other potential payments.
本社所在地 1405 du Parc-Technologique Blvd. Quebec City Quebec G1P 4P5 CAN
代表者氏名 Carolyn Egbert キャロリン・エグベルト
代表者役職名 Independent Chairman of the Board
電話番号 +1 843-900-3223
設立年月日 33117
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 56人
url www.aezsinc.com
nasdaq_url https://www.nasdaq.com/symbol/aezs
adr_tso
EBITDA EBITDA(百万ドル) 5.17900
終値(lastsale) 1.67
時価総額(marketcap) 27456069.2
時価総額 時価総額(百万ドル) 28.28272
売上高 売上高(百万ドル) 25.24500
企業価値(EV) 企業価値(EV)(百万ドル) 8.33672
当期純利益 当期純利益(百万ドル) 1.70700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AEterna Zentaris Inc. (USA) revenues increased from $504K to $24.8M. Net income totaled $11.8M vs. loss of $6.7M. Revenues reflect Licensing revenue increase from $220K to $24.7M. Net Income reflects Research and development costs net of r decrease of 70% to $1.8M (expense) Selling expenses decrease of 29% to $2.1M (expense).

 AEZSのテクニカル分析


 AEZSのニュース

   Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerzburg for Development of a Potential Oral Prophylactic Bacterial Vaccine Against COVID-19  2021/03/15 12:05:00 GlobeNewswire
- Company secures next step to continue to build-out pipeline of assets - Company exercised its option to enter into an exclusive license of…
   Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program for the Potential Treatment of Primary Hypoparathyroidism | MarketScreener  2021/03/11 13:05:02 MarketScreener
– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone fusion polypeptides covering the field of human use… | March 11, 2021
   4 Penny Stocks on the Run: Aeterna Zentaris (NASDAQ: AEZS), Alpine 4 Technologies (OTC US: ALPP), Enzolytics (OTC US: ENZC), and Ocugen (NASDAQ: OCGN) - Stocks News Feed  2021/02/10 13:40:12 Stocks News Feed
If January and February are a sign of things to come in 2021, traders and investors are going to make a lot of money this year. 4 penny stocks on the run are Aeterna Zentaris (NASDAQ: AEZS), Alpine 4 Technologies (OTCMKTS: ALPP), Enzolytics (OTCMKTS: ENZC), and Ocugen (NASDAQ: OCGN). HOW TO TRADE PENNY STOCKS First… Read More »4 Penny Stocks on the Run: Aeterna Zentaris (NASDAQ: AEZS), Alpine 4 Technologies (OTC US: ALPP), Enzolytics (OTC US: ENZC), and Ocugen (NASDAQ: OCGN)
   AEZS Stock: Aeterna Zentaris Climbs on COVID-19 News - CNA Finance  2021/02/02 13:35:49 CNA Finance
AEZS stock is flying in the market this morning after announcing an option to license a COVID-19 vaccine. Is this the next big short squeeze?
   Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference  2021/01/05 13:05:00 GlobeNewswire
CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical…
   AEZS Stock: Aeterna Zentaris Climbs on COVID-19 News - CNA Finance  2021/02/02 13:35:49 CNA Finance
AEZS stock is flying in the market this morning after announcing an option to license a COVID-19 vaccine. Is this the next big short squeeze?
   Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference  2021/01/05 13:05:00 GlobeNewswire
CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical…
   Aeterna Zentaris, Novo Nordisk amends macimorelin licensing pact (NASDAQ:AEZS)  2020/11/16 13:47:48 Seeking Alpha
Aeterna Zentaris (NASDAQ:AEZS) jumps 6% in premarket, on amendment of its existing license agreement with Novo Nordisk (NYSE:NVO) related to the developmen
   Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/06 13:35:00 GlobeNewswire
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021 – Continue to advance discussions to secure a…
   The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure  2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
   Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference  2021/01/05 13:05:00 GlobeNewswire
CHARLESTON, S.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical…
   Aeterna Zentaris, Novo Nordisk amends macimorelin licensing pact (NASDAQ:AEZS)  2020/11/16 13:47:48 Seeking Alpha
Aeterna Zentaris (NASDAQ:AEZS) jumps 6% in premarket, on amendment of its existing license agreement with Novo Nordisk (NYSE:NVO) related to the developmen
   Aeterna Zentaris Reports Third Quarter 2020 Financial Results and Provides Business Update  2020/11/06 13:35:00 GlobeNewswire
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021 – Continue to advance discussions to secure a…
   The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure  2020/11/03 12:38:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 2) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Immunovant Inc (NASDAQ: IMVT ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 2) AEterna Zentaris Inc. (NASDAQ: AEZS ) Aikido Pharma Inc (NASDAQ: AIKI ) Artelo Biosciences Inc (NASDAQ: ARTL ) Avita Therapeutics Inc (NASDAQ: RCEL ) Benitec Biopharma Inc (NASDAQ: BNTC ) BioCardia Inc (NASDAQ: BCDA ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Celsion Corporation (NASDAQ: CLSN ) Codiak BioSciences Inc (NASDAQ: CDAK ) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Entasis Therapeutics Holdings Inc (NASDAQ: ETTX ) FSD Pharma Inc (NASDAQ: HUGE ) Galecto Inc (NASDAQ: GLTO ) (went public Thursday) Hoth Therapeutics Inc (NASDAQ: HOTH ) Inhibrx Inc (NASDAQ: INBX ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Monopar Therapeutics Inc (NASDAQ: MNPR ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ) (halted dosing in Strimvelis study after it was linked to the development of leukemia in a patient) Orphazyme A S ADR (NASDAQ: ORPH ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) Stocks In Focus Aurinia Ends Dry Eye Disease Study Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) said topline results from its Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of …
   The Daily Biotech Pulse: Marinus Epilepsy Study Meets Goal, Novavax Reaches Vaccine Manufacturing Deal, Outset Medical's IPO  2020/09/15 11:55:39 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) 10X Genomics Inc (NASDAQ: TXG ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Avidity Biosciences Inc (NASDAQ: RNA ) BioLife Solutions Inc (NASDAQ: BLFS ) Denali Therapeutics Inc (NASDAQ: DNLI ) Guardant Health Inc (NASDAQ: GH ) Immunomedics, Inc. (NASDAQ: IMMU ) - announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD ) for $21 billion Inspire Medical Systems Inc (NYSE: INSP ) Kintara Therapeutics Inc (NASDAQ: KTRA ) Kura Oncology Inc (NASDAQ: KURA ) Nurix Therapeutics Inc (NASDAQ: NRIX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) (announced the appointment of Susan Kim as CFO, effective Sept. 28) Shockwave Medical Inc (NASDAQ: SWAV ) SI-Bone Inc (NASDAQ: SIBN ) Silk Road Medical Inc (NASDAQ: SILK ) Stoke Therapeutics Inc (NASDAQ: STOK ) Trillium Therapeutics Inc (NASDAQ: TRIL ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 14) Acorda Therapeutics Inc (NASDAQ: ACOR ) AEterna Zentaris Inc. (NASDAQ: AEZS ) BELLUS Health Inc (NASDAQ: BLU ) PainReform Ltd (NASDAQ: PRFX ) Predictive Oncology Inc (NASDAQ: POAI ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Stocks In Focus Marinus Reports Positive Late-Stage Readout In Epilepsy Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) announced positive top-line results from its registrational Phase 3 clinical trial, dubbed Marigold, evaluating the use of oral ganaxolone in children and young adults with CDKL5 deficiency disorder, a rare, genetic epilepsy with refractory seizures.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エテルナ・ゼンタリス AEZS AEterna Zentaris Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)